Intensified polarization for R&D among listed pharmas

R&D polarization is being intensified among listed pharmaceutical companies.

While there is a company investing more than 20% of their sales, a number of companies are still spending less than 1% of their sales into R&D.

Yakup Shinmoon(www.yakup.com) analyzed KOSPI and KOSDAQ listed pharmaceutical companies’ 2017 2^nd quarter reports, and the analysis showed they invest 7.7% of their sales int...